A Phase 3, Randomized, Open-Label, Multicenter, Global Study of First-Line Durvalumab + SoC Chemotherapy and Durvalumab + Tremelimumab and SoC Chemotherapy vs SoC Chemotherapy Alone in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Abstract

BACKGROUND Despite high response rates to first-Line (1L) standard of care (SoC) for locally advanced or metastatic urothelial cancer (UC) chemotherapy (gemcitabine + cisplatin or gemcitabine + carboplatin for patients who are cisplatin-ineligible [poor performance status, impaired renal function, comorbidities]), most patients experience disease progression. Novel strategies such